SCHEMBL11998014

SCHEMBL11998014

C[C@@H]1CC[C@H]([C@@H](O)[C@@H](N)Cc2ccccc2)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 1/20 0.41
SLC6A2 P23975 2/20 0.40
TAAR1 Q96RJ0 2/20 0.40
SIGMAR1 Q99720 2/20 0.40
MAOA P21397 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
CYP2A6 P11509 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
SLC15A1 P46059 1/20 0.39
EPHX1 P07099 1/20 0.38
CYP2D6 P10635 1/20 0.38
LAP3 P28838 3/20 0.37
ANPEP P15144 1/20 0.37
RNPEP Q9H4A4 1/20 0.37
DNPEP Q9ULA0 1/20 0.37
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
SLC1A1 P43005 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11998017 0.84 SLC15A1 (0.40) CSNK1ESLC6A2TAAR1SIGMAR1MAOA
SCHEMBL11998013 0.82 SLC15A1 (0.39) CSNK1ESLC6A2TAAR1SIGMAR1MAOA
SCHEMBL11998024 0.82 CSNK1E (0.39) CSNK1ESLC6A2TAAR1SIGMAR1MAOA
SCHEMBL11998011 0.81 AKR1C3 (0.40) CSNK1ESIGMAR1SLC15A1EPHX1SLC1A3
SCHEMBL7357671 0.80 SLC15A1 (0.44) CSNK1ESLC6A2TAAR1SIGMAR1MAOA
SCHEMBL11998010 0.80 SLC15A1 (0.44) CSNK1ESLC6A2TAAR1SIGMAR1MAOA
SCHEMBL6580113 0.80 SLC15A1 (0.44) CSNK1ESLC6A2TAAR1SIGMAR1MAOA
SCHEMBL11998023 0.80 SLC15A1 (0.44) CSNK1ESLC6A2TAAR1SIGMAR1MAOA
SCHEMBL10871667 0.78 EPHX2 (0.45) CSNK1ESLC6A2TAAR1SIGMAR1MAOA
SCHEMBL11998002 0.78 AGTR2 (0.40) SLC15A1LAP3DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130102593-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF PURDUE RESEARCH FOUNDATION 2013-04-25 US disclosed
US-20130059840-A1 SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2013-03-07 US disclosed
US-20120295894-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BILCER GEOFFREY M (US) 2012-11-22 US disclosed
US-20120214802-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF PURDUE RESEARCH FOUNDATION 2012-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059840-A1 SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BACE1, BACE2, GSAP CSNK1E 1137/4885SLC6A2 3873/4885TAAR1 4657/4885
US-20120295894-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BACE1, BACE2, APP CSNK1E 1331/4885SLC6A2 4243/4885TAAR1 4634/4885
US-20120214802-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BACE1, BACE2, APP CSNK1E 1331/4885SLC6A2 4243/4885TAAR1 4634/4885
US-20130102593-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BACE1, BACE2, APP CSNK1E 1331/4885SLC6A2 4243/4885TAAR1 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.